News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

  • In a clinical trial involving women with triple-negative breast cancer, patients who received the drugs carboplatin and/or bevacizumab in combination with standard chemotherapy prior to surgery were more likely to have their tumors disappear entirely from the breast, according to data presented by investigators during the 2014 San Antonio Breast Cancer Symposium.

Tags: BreastCancer

  • Adding a PI3K inhibitor to hormonal therapy for metastatic breast cancer may help overcome resistance to the hormonal therapy and delay disease progression, according to investigators from Dana-Farber Cancer Institute.

Tags: BreastCancer

  • Common variations in four genes related to brain inflammation or cells' response to damage from oxidation may contribute to the problems with memory, learning and other cognitive functions seen in children treated for acute lymphoblastic leukemia (ALL), according to research presented at the annual American Society of Hematology annual meeting in San Francisco.

Tags: ChildhoodCancer, Survivorship, Leukemia

  • A study led by Dana-Farber investigators found that a phase 1 trial of an immune checkpoint blocker found clinical benefit in nearly half of blood cancer patients who had relapsed following allogeneic stem cell transplantation.

Tags: MultipleMyeloma, Leukemia, Immunotherapy

  • Small cell lung cancer – a disease for which no new drugs have been approved for many years – has shown itself vulnerable to an agent that disables part of tumor cells’ basic survival machinery, researchers at Dana-Farber Cancer Institute and the Massachusetts Institute of Technology reported.

Tags: Genomics, LungCancer

  • Findings by Dana-Farber scientists and others show the disarray in the on-off mechanism – known as methylation – is one of the defining characteristics of cancer and helps tumors adapt to changing circumstances.

Tags: BasicResearch, Genomics

  • Dana-Farber researchers report that multiple myeloma is driven to spread by a subset of the myeloma cells within a patient’s body, and that attacking those specific subsets with targeted drugs may be better targets for therapy.

Tags: BasicResearch, MultipleMyeloma

  • Researchers report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant after pre-treatment with immunosuppressive drugs only. This is the first trial reporting successful transplant in dyskeratosis congenita (DC) patients without the use of any radiation or conventional cytotoxic chemotherapy beforehand.

Tags: chemotherapy, StemCellTransplant

  • Dana-Farber and colleagues report that an oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) in a phase 2 clinical trial.

Tags: Leukemia

  • The "molecular mail" sent by multiple myeloma cells provides clues to how well patients with the disease are likely to respond to treatment, according to a study by researchers at Dana-Farber Cancer.

Tags: BasicResearch, MultipleMyeloma

Showing 1-10 of 557 items